Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,447 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Miura R, Ono A, Nakahara H, Shirane Y, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Murakami E, Kawaoka T, Miki D, Tsuge M, Kishi T, Ohishi W, Sakamoto N, Arihiro K, Hayes CN, Oka S. Miura R, et al. Among authors: ono a. J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02185-w. Online ahead of print. J Gastroenterol. 2024. PMID: 39652104
Using Patient-Specific Contrast Enhancement Optimizer Simulation Software During the Transcatheter Aortic Valve Implantation-Computed Tomography Angiography in Patients With Aortic Stenosis.
Masuda T, Nakaura T, Higaki T, Funama Y, Matsumoto Y, Sato T, Okimoto T, Arao K, Imaizumi H, Arao S, Ono A, Hiratsuka J, Awai K. Masuda T, et al. Among authors: ono a. J Comput Assist Tomogr. 2024 Sep-Oct 01;48(5):759-762. doi: 10.1097/RCT.0000000000001603. Epub 2024 Apr 8. J Comput Assist Tomogr. 2024. PMID: 38595080
[12. Noncontrast MR Angiography].
Ono A. Ono A. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2022;78(10):1210-1216. doi: 10.6009/jjrt.2022-2085. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2022. PMID: 36261357 Free article. Japanese. No abstract available.
Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma.
Miura R, Ono A, Yano S, Amioka K, Naruto K, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Nakahara T, Murakami E, Kawaoka T, Miki D, Tsuge M, Hayes CN, Oka S. Miura R, et al. Among authors: ono a. Medicine (Baltimore). 2024 Aug 23;103(34):e39289. doi: 10.1097/MD.0000000000039289. Medicine (Baltimore). 2024. PMID: 39288227 Free PMC article.
1,447 results